Anavex Life Sciences Corp.

Alexandre Vamvakides

Tangui Maurice

This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.

ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection

The present invention involves new and original sigma receptors ligands: (Mono- or dialkylaminoalkyl)-&#x3b3;-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl)benzene alkylamines, the N,N Dialkyl &#x3b1;-[(adamantyl-1)benzyloxy-2]alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.

Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity

Growing community of inventors

Ymittos Attikis, Greece

Alexandre Vamvakides